Search for more clinical trials
Effects of Chemotherapy on Circulating Tumor Cells and Recurrences in Cervical Cancer Patients
Conditions
Cervical Cancer
Conditions: official terms
Neoplastic Cells, Circulating - Uterine Cervical Neoplasms
Conditions: Keywords
cervical cancer
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Prospective
Overall Status
Not yet recruiting
Summary
Cervical cancer is a major health problem for Chinese women. It is estimated that nearly 100,000 new cervical cancer cases occur in China every year, which accounts for about 20 percent of global new cases. Surgery and radiotherapy are two major radical treatment methods for IB-IIB cervical cancer. Unlike the United States and some other countries, most of operable women with IB-IIB cervical cancer received radical surgery other than radiotherapy in China. Patients with recurrence risk factors (lymph node metastasis, deep stromal invasion, positive lymphatic vascular space, et al. ) also received adjuvant therapy after surgery, such as radiotherapy or chemoradiotherapy that are recommended in the NCCN guidelines. However, in China a substantial part of patients especially those admitted to tertiary hospitals received several courses of chemotherapy instead of radiotherapy if they had recurrence risk factors .
In our previous study, we found that patients with intermediate risk factors (deep stromal invasion, positive lymphatic vascular space, bulky tumor>4cm) had better disease-free survival and recurrence-free survival when they received chemotherapy compared with radiotherapy. The objective in this study is to investigate whether the advantage of postoperative chemotherapy is a result of circulating tumor cells (CTC) in some of the patients with intermediate risk factors.
In our previous study, we found that patients with intermediate risk factors (deep stromal invasion, positive lymphatic vascular space, bulky tumor>4cm) had better disease-free survival and recurrence-free survival when they received chemotherapy compared with radiotherapy. The objective in this study is to investigate whether the advantage of postoperative chemotherapy is a result of circulating tumor cells (CTC) in some of the patients with intermediate risk factors.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 70 Years
Minimum Age: 18 Years
Gender: Female
Criteria: Inclusion Criteria:
- Patients with histologically confirmed Ib~IIa （FIGO）cervical carcinoma without previous treatments
- Age between 18-70
- With the presence of these three pathological risk factors after radical surgery:(1) positive lymphatic vascular space,(2)outer one-third invasion of the cervical stroma, (3) bulky tumor≥4cm
- At least 3 months of disease-free survival
Exclusion Criteria:
- The presence of other uncontrolled life-threatening disease (Suffering from myocardial infarction or stroke, or unstable angina, decompensated heart failure, or a history of deep vein thrombosis)
- Receiving other anti-cancer therapy, such as traditional Chinese drug
- Don't be able to finish the whole treatment(chemotherapy or radiotherapy)
- liver dysfunction (ALT、AST>2.5×ULN)
- renal dysfunction (Creatinine>1.5×ULN)
- WBC<4,000/mm3 or PLT<100,000/mm3
- Received preoperative radiotherapy
- Patients with histologically confirmed Ib~IIa （FIGO）cervical carcinoma without previous treatments
- Age between 18-70
- With the presence of these three pathological risk factors after radical surgery:(1) positive lymphatic vascular space,(2)outer one-third invasion of the cervical stroma, (3) bulky tumor≥4cm
- At least 3 months of disease-free survival
Exclusion Criteria:
- The presence of other uncontrolled life-threatening disease (Suffering from myocardial infarction or stroke, or unstable angina, decompensated heart failure, or a history of deep vein thrombosis)
- Receiving other anti-cancer therapy, such as traditional Chinese drug
- Don't be able to finish the whole treatment(chemotherapy or radiotherapy)
- liver dysfunction (ALT、AST>2.5×ULN)
- renal dysfunction (Creatinine>1.5×ULN)
- WBC<4,000/mm3 or PLT<100,000/mm3
- Received preoperative radiotherapy
Location
Tongji Hospital of HUST
Wuhan, Hubei, China
Status: Not yet recruiting
Contact: Ma Ding, M.D. - 86-27-8362681 - dma@tjh.tjmu.edu.cn
Start Date
March 2010
Completion Date
January 2014
Sponsors
Huazhong University of Science and Technology
Source
Huazhong University of Science and Technology
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page